Miniatura

Fitxers

706481.pdf (339.17 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-01-09

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/175933

A controlled trial of rivaroxaban after transcatheter aortic-valve replacement

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJMoa1911425

Resum

Background: whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. Methods: we randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was the composite of death or thromboembolic events. The primary safety outcome was major, disabling, or life-threatening bleeding. The trial was terminated prematurely by the data and safety monitoring board because of safety concerns. Results: after a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; P = 0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P = 0.08). A total of 64 deaths occurred in the rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53). Conclusions: in patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.).

Matèries

Aspirina, Ús terapèutic, Catèters

Matèries (anglès)

Aspirin, Therapeutic use, Catheters

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)

Citació

DANGAS, George d., Tijssen Jan G.P., WÖHRLE, Jochen, SØNDERGAARD, Lars, GILARD, Martine, MÖLLMANN, Helge, MAKKAR, Raj r., Herrmann Howard C., GIUSTINO, Gennaro, BALDUS, Stephan, BACKER, Ole de, GUIMARÃES, Ana h.c., GULLESTAD, Lars, KINI, Annapoorna, VON LEWINSKI, Dirk, MACK, Michael, MORENO, Raúl, SCHÄFER, Ulrich, SEEGER, Julia, TCHÉTCHÉ, Didier, THOMITZEK, Karen, VALGIMIGLI, Marco, VRANCKX, Pascal, WELSH, Robert c., WILDGOOSE, Peter, VOLKL, Albert a., ZAZULA, Ana, VAN AMSTERDAM, Roland g.m., MEHRAN, Roxana, WINDECKER, Stephan, CEQUIER FILLAT, Àngel r., GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. _New England Journal of Medicine_. 2020. Vol. 382, núm. 2, pàgs. 120-129. [consulta: 25 de gener de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/175933]

Exportar metadades

JSON - METS

Compartir registre